Equibles does not estimate personal net worth.
Get an email with a short summary when Gilead Sciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get GILD alertsThe proxy statement of Gilead Sciences, Inc. reports total compensation of $8,111,131 for Merdad Parsey in fiscal 2024, including a base salary of $1,141,486. Disclosed compensation is on record for 6 fiscal years. Merdad Parsey has spoken on 1 earnings call across 1 company, most recently for Gilead Sciences, Inc. on February 6, 2024. Gilead Sciences, Inc. is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Gilead Sciences, Inc. includes Daniel P. O’Day (CEO), Robin L. Washington (CFO), Diane E. Wilfong (Chief Accounting Officer) and 7 others.
“We've had a busy start to 2024, and I'll begin by discussing the results of our Evoca1 study in second-in-line-plus metastatic non-small-cell lung cancer and our Phase III oak tree study of obeldecevir in standard-risk non-hospitalized patients with COVID-19.”
Source not stated
Drug Manufacturers - General · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Gilead Sciences, Inc. (GILD) | M.D., Ph.D. Chief Medical Officer | $1,141,486 | $8,111,131 |
| 2023 | Gilead Sciences, Inc. (GILD) | M.D., Ph.D. Chief Medical Officer | $1,108,215 | $8,386,847 |
| 2022 | Gilead Sciences, Inc. (GILD) | M.D., Ph.D. Chief Medical Officer | $1,072,800 | $9,037,214 |
| 2021 | Gilead Sciences, Inc. (GILD) | M.D., Ph.D. Chief Medical Officer | $1,024,808 | $6,516,679 |
| 2020 | Gilead Sciences, Inc. (GILD) | M.D., Ph.D. Chief Medical Officer | $1,038,462 | $7,180,355 |
| 2019 | Gilead Sciences, Inc. (GILD) | M.D., Ph.D. Chief Medical Officer | $119,231 | $3,119,553 |
